Can risk prediction models help us individualise stillbirth prevention? A systematic review and critical appraisal of published risk models.

Epidemiology fetal medicine model perinatal prediction serum screening stillbirth systematic reviews

Journal

BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741

Informations de publication

Date de publication:
01 2021
Historique:
accepted: 02 09 2020
pubmed: 8 9 2020
medline: 5 3 2021
entrez: 7 9 2020
Statut: ppublish

Résumé

Stillbirth prevention is an international priority - risk prediction models could individualise care and reduce unnecessary intervention, but their use requires evaluation. To identify risk prediction models for stillbirth, and assess their potential accuracy and clinical benefit in practice. MEDLINE, Embase, DH-DATA and AMED databases were searched from inception to June 2019 using terms relevant to stillbirth, perinatal mortality and prediction models. The search was compliant with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Studies developing and/or validating prediction models for risk of stillbirth developed for application during pregnancy. Study screening and data extraction were conducted in duplicate, using the CHARMS checklist. Risk of bias was appraised using the PROBAST tool. The search identified 2751 citations. Fourteen studies reporting development of 69 models were included. Variables consistently included were: ethnicity, body mass index, uterine artery Doppler, pregnancy-associated plasma protein and placental growth factor. For almost all models there were significant concerns about risk of bias. Apparent model performance (i.e. in the development dataset) was highest in models developed for use later in pregnancy and including maternal characteristics, and ultrasound and biochemical variables, but few were internally validated and none were externally validated. Almost all models identified were at high risk of bias. There are first-trimester models of possible clinical benefit in early risk stratification; these require validation and clinical evaluation. There were few later pregnancy models but, if validated, these could be most relevant to individualised discussions around timing of birth. Prediction models using maternal factors, blood tests and ultrasound could individualise stillbirth prevention, but existing models are at high risk of bias.

Sections du résumé

BACKGROUND
Stillbirth prevention is an international priority - risk prediction models could individualise care and reduce unnecessary intervention, but their use requires evaluation.
OBJECTIVES
To identify risk prediction models for stillbirth, and assess their potential accuracy and clinical benefit in practice.
SEARCH STRATEGY
MEDLINE, Embase, DH-DATA and AMED databases were searched from inception to June 2019 using terms relevant to stillbirth, perinatal mortality and prediction models. The search was compliant with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.
SELECTION CRITERIA
Studies developing and/or validating prediction models for risk of stillbirth developed for application during pregnancy.
DATA COLLECTION AND ANALYSIS
Study screening and data extraction were conducted in duplicate, using the CHARMS checklist. Risk of bias was appraised using the PROBAST tool.
RESULTS
The search identified 2751 citations. Fourteen studies reporting development of 69 models were included. Variables consistently included were: ethnicity, body mass index, uterine artery Doppler, pregnancy-associated plasma protein and placental growth factor. For almost all models there were significant concerns about risk of bias. Apparent model performance (i.e. in the development dataset) was highest in models developed for use later in pregnancy and including maternal characteristics, and ultrasound and biochemical variables, but few were internally validated and none were externally validated.
CONCLUSIONS
Almost all models identified were at high risk of bias. There are first-trimester models of possible clinical benefit in early risk stratification; these require validation and clinical evaluation. There were few later pregnancy models but, if validated, these could be most relevant to individualised discussions around timing of birth.
TWEETABLE ABSTRACT
Prediction models using maternal factors, blood tests and ultrasound could individualise stillbirth prevention, but existing models are at high risk of bias.

Identifiants

pubmed: 32894620
doi: 10.1111/1471-0528.16487
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

214-224

Subventions

Organisme : Medical Research Council
ID : MR/P027938/1
Pays : United Kingdom
Organisme : Stillbirth and Neonatal Death Society

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 John Wiley & Sons Ltd.

Références

Kleinrouweler CE, Cheong-See F, Collins G, Kwee A, Thangaratinam S, Khan KS, et al. Prognostic models in obstetrics: available, but far from applicable. Am J Obstet Gynecol 2016;214:79-90.
Blencowe H, Cousens S, Jassir FB, Say L, Chou D, Mathers C, et al. National, regional, and worldwide estimates of stillbirth rates in 2015, with trends from 2000: a systematic analysis. Lancet Glob Heal 2016;4:e98-e108.
Widdows K, Roberts S, Camacho E, Heazell A. Evaluation of the implementation of the Saving Babies’ Lives Care Bundle in early adopter NHS Trusts in England. Manchester, UK; 2018.
Moons KGM, De GJAH, Bouwmeester W, Vergouwe Y, Mallett S. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: The CHARMS checklist. PLoS Med 2014;11:e1001744.
Wollf R, Whiting P, Mallett S, Riley R, Westwood M, Kleijnen J, et al. PROBAST: a risk of bias tool for prediction modelling studies. Cochrane Colloqium. Vienna; 2015.
Riley R, van der Windt D, Croft P. Prognosis Research in Healthcare: Concepts, Methods and Impact. Oxford: Oxford University Press; 2019.
Steyerberg EW, Moons KGM, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med 2013;10:e1001381.
Tavares Da Silva F, Gonik B, McMillan M, Keech C, Dellicour S, Bhange S, et al. Stillbirth: Case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety data. Vaccine 2016;34:6057-68.
Debray TPA, Damen JAAG, Snell KIE, Ensor J, Hooft L, Reitsma JB, et al. A guide to systematic review and meta-analysis of prediction model performance. BMJ 2017;356:i6460.
Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. J Clin Epidemiol 2009;62:1006-12.
Geersing G-J, Bouwmeester W, Zuithoff P, Spijker R, Leeflang M, Moons K. Search filters for finding prognostic and diagnostic prediction studies in MEDLINE to enhance systematic reviews. PLoS One 2012;7:e32844.
Ingui BJ, Rogers MA. Searching for clinical prediction rules in MEDLINE. J Am Med Inform Assoc 2001;8:391-7.
Steyerberg EW. Clinical Prediction Models. New York: Springer New York; 2009. (Statistics for Biology and Health).
Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-9.
Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007;165:710-8.
Courvoisier DS, Combescure C, Agoritsas T, Gayet-Ageron A, Perneger TV. Performance of logistic regression modeling: beyond the number of events per variable, the role of data structure. J Clin Epidemiol 2011;64:993-1000.
Riley RD, Snell KIE, Ensor J, Burke DL, Harrell FE, Moons KGM, et al. Minimum sample size for developing a multivariable prediction model: Part I - Continuous outcomes. Stat Med 2019;38:1262-75.
van Smeden M, de Groot JAH, Moons KGM, Collins GS, Altman DG, Eijkemans MJC, et al. No rationale for 1 variable per 10 events criterion for binary logistic regression analysis. BMC Med Res Methodol 2016;16:163.
Riley RD, Snell KIE, Ensor J, Burke DL, Harrell FE, Moons KGM, et al. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med 2018:1-21.
Kayode GA, Grobbee DE, Amoakoh-Coleman M, Adeleke IT, Ansah E, de Groot JAH, et al. Predicting stillbirth in a low resource setting. BMC Pregnancy Childbirth 2016;16:1-8.
Payne BA, Groen H, Ukah UV, Ansermino JM, Bhutta Z, Grobman W, et al. Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension. Pregnancy Hypertens 2015;5:315-21.
Akolekar R, Zaragoza E, Poon LCY, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008;32:732-9.
Aupont JE, Akolekar R, Illian A, Neonakis S, Nicolaides KH. Prediction of stillbirth from placental growth factor at 19-24 weeks. Ultrasound Obstet Gynecol 2016;48:631-5.
Vellamkondu A, Vasudeva A, Bhat RG, Kamath A, Amin SV, Rai L, et al. Risk assessment at 11-14-week antenatal visit: a tertiary referral center experience from South India. J Obstet Gynecol India 2017;67:421-7.
Akolekar R, Tokunaka M, Ortega N, Syngelaki A, Nicolaides KH. Prediction of stillbirth from maternal factors, fetal biometry and uterine artery Doppler at 19-24 weeks. Ultrasound Obstet Gynecol. 2016;48:624-30.
Yerlikaya G, Akolekar R, Mcpherson K, Syngelaki A, Nicolaides KH. Prediction of stillbirth from maternal demographic and pregnancy characteristics. Ultrasound Obstet Gynecol 2016;48:607-12.
Akolekar R, Machuca M, Mendes M, Paschos V, Nicolaides KH. Prediction of stillbirth from placental growth factor at 11-13 weeks. Ultrasound Obstet Gynecol 2016;48:618-23.
Mastrodima S, Akolekar R, Yerlikaya G, Tzelepis T, Nicolaides KH. Prediction of stillbirth from biochemical and biophysical markers at 11-13 weeks. Ultrasound Obstet Gynecol 2016;48:613-7.
Åmark H, Westgren M, Persson M. Prediction of stillbirth in women with overweight or obesity - A register-based cohort study. PLoS One 2018;13:1-11.
Khalil A, Morales-Rosellõ J, Townsend R, Morlando M, Papageorghiou A, Bhide A, et al. Value of third-trimester cerebroplacental ratio and uterine artery Doppler indices as predictors of stillbirth and perinatal loss. Ultrasound Obstet Gynecol 2016;47:74-80.
Familiari A, Scala C, Morlando M, Bhide A, Khalil A, Thilaganathan B. Mid-pregnancy fetal growth, uteroplacental Doppler indices and maternal demographic characteristics: role in prediction of stillbirth. Acta Obstet Gynecol Scand 2016;95:1313-8.
Trudell AS, Tuuli MG, Colditz GA, Macones GA, Odibo AO. A stillbirth calculator: Development & internal validation of a clinical prediction model to quantify stillbirth risk. PLoS One 2017;12:1-13.
Akolekar R, Bower S, Flack N, Bilardo CM, Nicolaides KH. Prediction of miscarriage and stillbirth at 11-13 weeks and the contribution of chorionic villus sampling. Prenat Diagn 2011;31:38-45.
Kingdon C, Roberts D, Turner MA, Storey C, Crossland N, Finlayson KW, et al. Inequalities and stillbirth in the UK: a meta-narrative review. BMJ Open 2019;9:e029672.
van Smeden M, Moons KG, de Groot JA, Collins GS, Altman DG, Eijkemans MJ, et al. Sample size for binary logistic prediction models: Beyond events per variable criteria. Stat Methods Med Res 2018; 096228021878472.
Smith GC, Yu CK, Papageorghiou AT, Maria Cacho A, Nicolaides KH. Maternal uterine artery Doppler flow velocimetry and the risk of stillbirth. Obstet Gynecol 2007;109:144-51.
Grivell RM, Alfirevic Z, Gyte GML, Devane D. Antenatal cardiotocography for fetal assessment. Cochrane Database Syst Rev 2015; 2015(9):CD007863.
Bishop JC, Dunstan FD, Nix BJ, Reynolds TM, Swift A. All MoMs are not equal: some statistical properties associated with reporting results in the form of multiples of the median. Am J Hum Genet 1993;52:425-30.
Mackie FL, Whittle R, Morris RK, Hyett J, Riley RD, Kilby MD. First-trimester ultrasound measurements and maternal serum biomarkers as prognostic factors in monochorionic twins: a cohort study. Diagnostic Progn Res 2019;3:1-9.
Norman JE, Heazell AEP, Rodriguez A, Weir CJ, Stock SJE, Calderwood CJ, et al. Awareness of fetal movements and care package to reduce fetal mortality (AFFIRM): a stepped wedge, cluster-randomised trial. Lancet 2018;392:1629-38.
Muglu J, Rather H, Arroyo-Manzano D, Bhattacharya S, Balchin I, Khalil A, et al. Risks of stillbirth and neonatal death with advancing gestation at term: A systematic review and meta-analysis of cohort studies of 15 million pregnancies. Smith GC, editor. PLoS Med 2019;16:e1002838.
Knight M, Bunch K, Tuffnell D, Shakespeare J, Kotnis R, Kenyon S, et al. Saving Lives, Improving Mothers’ Care lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2015-17. Oxford; 2019.
Lockie E, Mccarthy EA, Hui L, Churilov L. Feasibility of using self-reported ethnicity in pregnancy according to the gestation-related optimal weight classification: a cross-sectional study. BJOG 2018;125:704-9.
Duffy JMN, Ziebland S, von Dadelszen P, McManus RJ. Tackling poorly selected, collected, and reported outcomes in obstetrics and gynecology research. Am J Obstet Gynecol 2019;220:71.e1.e4.

Auteurs

R Townsend (R)

Molecular and Clinical Sciences Research Institute, St George's, University of London and St George's University Hospitals NHS Foundation Trust, London, UK.
Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, UK.

A Manji (A)

Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, UK.

J Allotey (J)

Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
Pragmatic Clinical Trials Unit, Barts and the London, School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Aep Heazell (A)

Saint Mary's Hospital, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Faculty of Biology, Medicine and Health, Maternal and Fetal Health Research Centre, School of Medical Sciences, University of Manchester, Manchester, UK.

L Jorgensen (L)

Katie's Team, East London, UK.

L A Magee (LA)

School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.

B W Mol (BW)

Department of Obstetrics and Gynaecology, School of Medicine, Monash University, Melbourne, Australia.

Kie Snell (K)

Centre for Prognosis Research, School of Primary, Community and Social Care, Keele University, Keele, UK.

R D Riley (RD)

Centre for Prognosis Research, School of Primary, Community and Social Care, Keele University, Keele, UK.

J Sandall (J)

Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, St Thomas' Hospital, London, UK.

Gcs Smith (G)

Department of Obstetrics and Gynaecology, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.

M Patel (M)

Sands (Stillbirth and Neonatal Death Society), London, UK.

B Thilaganathan (B)

Molecular and Clinical Sciences Research Institute, St George's, University of London and St George's University Hospitals NHS Foundation Trust, London, UK.
Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, UK.

P von Dadelszen (P)

School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.

S Thangaratinam (S)

Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
Pragmatic Clinical Trials Unit, Barts and the London, School of Medicine and Dentistry, Queen Mary University of London, London, UK.

A Khalil (A)

Molecular and Clinical Sciences Research Institute, St George's, University of London and St George's University Hospitals NHS Foundation Trust, London, UK.
Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH